Gene therapy was once hailed as the transformative breakthrough for hemophilia—the long-awaited cure that would change everything. But reality has been more nuanced, and many people in the community have been hesitant to embrace it. Some…
Join Dr. Young, speaking on behalf of HEMA Biologics, for an informative conversation about a treatment option for hemophilia A or B with inhibitors. This session will share helpful insights to help you better understand your options and feel more…
The Bleeding Disorders Research Collaborative (BDRC) aims to advance an accessible standard of care and quality of life for all people living with inheritable bleeding disorders. This goal will be achieved through collaborative and meaningful…
Federal: 2025 Bleeding Disorders Conference NBDF wrapped up another successful Bleeding Disorders Conference. The policy team was busy with sessions on blood and product safety, access to insurance, and…
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for VONVENDI®, which expands its indication to include prophylaxis use to reduce the frequency of bleeding episodes in adults with von Willebrand…
Pathway to Cures, NBDF’s venture philanthropy fund, is an investor in Be Biopharma, Inc., a clinical-stage company developing engineered B cell medicines. Be Biopharma recently announced the first participant treated with their therapy BE-101…
#block-recentonlineeducation {
display:none;
}
Learn About Anti-TFPI TreatmentA new treatment option for people who have hemophilia A or B with or without inhibitors is called Anti-TFPI. In this 3D video we will show how Anti-TFPI treatment…
Decades of advocacy spearheaded by the World Federation of Hemophilia (WFH) have resulted in a victory for the global bleeding disorders community. The World Health Organization (WHO) Model List of Essential Medicines (EML) has been updated to…
Speakers: Lindsey George, MD; John Morris, PhD; Bill MauritsThis session of the Research Journal Club will focus on gene therapy. Gene therapy for hemophilia A is now commercially available in some countries. While early patient…
Speakers: Maria Santaella, PhD(c), MSN, RN-BC, CPHON; Michael Recht, MD, PhD, MBA; Sammie ValadezDiscover how the National Research Blueprint (NRB) has evolved into the Bleeding Disorders Research Collaborative (BDRC). This session…